BPC-157 Product Description
BPC-157 is a linear, unmodified 15-residue peptide with an unusually proline-rich core. Three consecutive proline residues at positions 3 through 5, plus two more at positions 8 and 11, give the molecule a constrained backbone and account for its reported resistance to enzymatic degradation in acidic media.
That stability profile is the main reason it appears so frequently in preclinical literature. Most research peptides of comparable length are studied only in tightly controlled buffer systems; BPC-157 has been characterized across a wider range of experimental conditions, which has produced a correspondingly large body of published mechanistic work.
While not naturally occurring as an isolated fragment, its parent protein contributes to gastrointestinal protection and repair. The peptide exhibits multifaceted mechanisms, including tissue repair promotion via activation of growth hormone receptors and pathways like JAK2, which enhance collagen synthesis and fibroblast activity.
Compound Information
Property Value Synonyms Body Protection Compound 157; Gastric Pentadecapeptide BPC 157; Bepecin; PL 14736 CAS Number 137525-51-0 PubChem CID 9941957 Molecular Formula C62H98N16O22 Molecular Weight 1419.56 g/mol Amino Acid Sequence GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) Sequence Length 15 residues Source Synthetic InChIKey HEEWEZGQMLZMFE-RKGINYAYSA-N Purity ≥99% (HPLC) Appearance Lyophilized white powder Solubility Soluble in water; soluble in DMSO Storage -20°C, protect from light
BPC-157 Peptide Structure
Source: PubChem
Storage and Handling
Store the lyophilized compound at -20°C, sealed and protected from light. After reconstitution, store at 2°C to 8°C and use promptly. Allow the vial to reach room temperature before opening to limit moisture uptake. Maintain aseptic handling to preserve compound integrity.
Lyophilized Format
This compound ships in lyophilized (freeze-dried) form. Freeze-drying supports long-term storage stability and preserves compound integrity. No fillers are added.
BPC-157 Research
The most closely characterized mechanism for BPC-157 is its interaction with the nitric oxide system. In isolated rat aorta preparations, the peptide produced concentration-dependent vasodilation that was endothelium-dependent and abolished by L-NAME, and co-immunoprecipitation work traced the response to phosphorylation of Src, caveolin-1, and endothelial nitric oxide synthase, with reduced binding between caveolin-1 and eNOS [1]. A broader review of the peptide’s relationship to the nitric oxide system describes its competing interactions with both L-arginine and L-arginine analogues across a range of experimental models [2].
A second well-documented line of work concerns growth factor receptor expression. cDNA microarray analysis of rat Achilles tendon fibroblasts identified the growth hormone receptor as one of the most abundantly up-regulated genes following exposure to the peptide, with concentration- and time-dependent increases confirmed at both mRNA and protein level, and downstream Janus kinase 2 activation observed on subsequent growth hormone stimulation [3]. Related work in the same cell system reported changes in tendon outgrowth, cell survival, and cell migration in culture [4].
Angiogenic signaling is the third major thread. Published reviews position the peptide alongside standard angiogenic growth factors and summarize the vascular observations recorded across models of tendon, ligament, muscle, and bone repair [5], with a dedicated review covering its relationship to blood vessel formation specifically [6]. Wider syntheses cover the full published record in tissue-repair research models [7] and in striated, smooth, and cardiac muscle preparations [8].
A 2025 systematic review examined the peptide from a musculoskeletal research perspective, screening 544 articles published between 1993 and 2024 and including 36 studies, of which 35 were preclinical [9]. The authors noted that the compound lacks FDA approval and that the published record remains overwhelmingly preclinical.
The Proline-Rich Core and Analytical Handling
The GEPPPGKPADDAGLV sequence carries five proline residues, which restricts backbone rotation and is the structural basis for the peptide’s reported stability in acidic conditions [7]. That same rigidity affects chromatographic behavior, so laboratories verifying identity by HPLC should expect retention characteristics distinct from comparable-length linear peptides. Reviewing our guide to reading a peptide COA before analysis is worthwhile.
Research Area In Vitro Application Nitric oxide signaling Src, caveolin-1, and eNOS phosphorylation assays in endothelial preparations Growth factor receptor expression Growth hormone receptor and JAK2 pathway profiling in tendon fibroblast culture Angiogenesis Endothelial tube formation and vascular marker expression assays Cell migration and survival Fibroblast outgrowth and migration assays in tissue-repair research models Peptide stability Analytical characterization of proline-rich sequences under varied pH conditions
References
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/ Sikiric P, Seiwerth S, Rucman R, et al. (2014). Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113190990411 Chang CH, Tsai WC, Hsu YH, Pang JS. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/ Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. https://doi.org/10.1152/japplphysiol.00945.2010 Seiwerth S, Rucman R, Turkovic B, et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. https://doi.org/10.2174/1381612824666180712110447 Seiwerth S, Brcic L, Vuletic LB, et al. (2014). BPC 157 and blood vessels. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990421 Seiwerth S, Milavic M, Vukojevic J, et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.627533 Staresinic M, Japjec M, Vranes H, et al. (2022). Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. https://doi.org/10.3390/biomedicines10123221 Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
Certificate of Analysis (COA) for Every Batch
A Certificate of Analysis (COA) is a document that verifies a compound’s identity, purity, and batch quality through independent laboratory testing. Every compound from BioLongevity Labs ships with a COA tied to its specific batch, so researchers can confirm exactly what they received before it enters a protocol.
Each COA reports results from third-party laboratory analysis, including:
High-performance liquid chromatography (HPLC) for purity, typically confirmed at 99% or higher Liquid chromatography mass spectrometry (LC-MS) for molecular identity and mass confirmation Sterility and endotoxin screening where applicable Chemical contaminant and residual solvent checks
COAs are sourced from independent certified labs rather than in-house testing alone, giving researchers a verifiable record of molecular integrity for each batch. All compounds are supplied for research use only.
Review the COAs for this batch below, or browse the full COA library.
BPC-157 (261571)
BPC-157 (261469)
BPPC-157 (260818)
BPC-157 (11994)
Endotoxin BPC-157
BPC-157 (11363)
BPC-157 (251528)
BPC-157 (251528E)
Endotoxin BPC-157
BPC157(10453)
BPC-157(2502270002)
×